CLOs on the Move

MedLite ID

www.medliteid.com

 
MedLite ID is an easy-to-use, disposable medical device that enables clinicans to accurately and efficiently identify a single medication infusion line against similar infusion lines in any light setting. The ninth leading cause of medical-error deaths in the United States involves infusion line confusion, and nearly 65 percent of those cases are related to the medication infusion line. MedLite ID eliminates infusion confusion by providing indicators with built-in wireless light technology at the medication bag, connector, and to patient. Each MedLite ID device is unique to its individual medication infusion line and cuts the process of infusion line identification to ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medliteid.com
  • Atwood Innovation Plaza Suite 108 453 S 600 E.
    St. George, UT USA 84770
  • Phone: 435.652.7741

Executives

Name Title Contact Details

Similar Companies

All Imaging Systems

All Imaging Systems is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primus Sterilizer

Primus Sterilizer is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

New England Home Therapies

New England Home Therapies is a Southborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luminetx Corporation

Luminetx Corporation is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.